14-10-2026 14:15 via wallstreet-online.de

With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge

Velocity Bioworks' San Antonio facility offers process development, analytical services, and early-phase clinical drug substance manufacturing for biotechnology companies evaluating U.S.-based production SAN ANTONIO, TX / ACCESS Newswire / October …
Weiterlesen »